| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 88.70 | 2.58 (+3.00%) | 14.32 - 88.73 | 749.4 thousand |
Market data as of 4:00PM 05/16/12. Quotes are delayed by at least 15 min.
| Open | 86.01 |
|---|---|
| Previous Close | 86.12 |
| Day's Range | 86.00 - 88.73 |
| Market Cap | 3.2B |
| Avg Volume (10 Day) | 818.2K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.86 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
No news headlines available for MDVN
| MDVN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 34.19% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 2.32 | |
| LT Debt/Equity | 2.32 | |
| Earnings Yield | -- | |
| Price/Sales | 37.84 |
| Company | Last | Change |
|---|---|---|
| Incyte Corp | 23.70 | +4.18% |
| Human Genome Sciences Inc | 14.25 | -2.13% |
| ARIAD Pharmaceuticals Inc | 17.52 | +1.45% |
| Onyx Pharmaceuticals Inc | 43.37 | +0.12% |
| Jazz Pharmaceuticals PLC | 45.19 | -0.07% |
Data is delayed by at least 15 min.